Purpose: Noninvasive prognostic biomarkers to inform clinical decision-making are an urgent unmet need for the management of patients with glioblastoma (GBM). We previously showed that higher circulating cell-free DNA (ccfDNA) concentration is associated with worse survival in GBM. However, the biology underlying this is unknown. Experimental Design: We prospectively enrolled 129 patients with treatment-naïve GBM with blood drawn prior to initial resection (baseline) and at the time of the first postradiotherapy MRI. We performed ccfDNA methylation deconvolution to determine cellular sources of ccfDNA. ELISA was performed to detect citrullinated histone 3 (citH3), a marker of neutrophil extracellular traps (NET). Multiplex proteomic analysis was used to measure soluble inflammatory proteins. Results: We found that neutrophils contributed the highest proportion of prognostic ccfDNA. The percentage of ccfDNA derived from neutrophils was correlated with total [ccfDNA] but only in patients receiving preoperative corticosteroids. At baseline and on therapy, [citH3] was significantly higher in the plasma of patients with GBM receiving corticosteroids compared with corticosteroid-naïve GBM or no-cancer controls. Unsupervised hierarchical clustering of ccfDNA methylation patterns yielded two clusters, with one enriched for patients with the NETosis phenotype and who received corticosteroids. Unsupervised clustering of circulating inflammatory proteins yielded similar results. Conclusions: These data suggest neutrophil-mediated NETosis is the dominant source of prognostic ccfDNA in patients with GBM and may be associated with glucocorticoid exposure. If further studies show that pharmacological inhibition of NETosis can mitigate the deleterious effects of corticosteroids, these plasma markers will have important clinical utility as noninvasive correlative biomarkers.
PURPOSE: Because of tumor heterogeneity and sampling error, next-generation sequencing (NGS) of glioblastoma (GBM) tumors may provide an incomplete picture of the somatic mutational landscape. We hypothesized that simultaneous targeted NGS of matched tumor tissue and cerebrospinal fluid (CSF), obtained during craniotomy for resection of GBM, would lead to identification of clinically relevant variants not detected by tissue NGS alone. METHODS: We enrolled 50 patients undergoing resection of newly diagnosed (n = 15) or recurrent (n = 35) GBM. CSF was collected intraoperatively via the subarachnoid space (n = 25) or lateral ventricle (n = 25) and assayed by NGS using a hybrid capture liquid biopsy panel. Matched tumor tissue also underwent large panel hybrid capture NGS testing. RESULTS: CSF samples from 28 of 50 patients (56%) passed quality control metrics. At least one CSF variant was detected in 25 of 28 patients (89%), and 22 of 28 patients had matched tissue sequencing results available. In these 22 patients (primary analysis cohort), the median number of variants detected in CSF was higher than in tissue (3 v 2 variants, respectively; P = .0035), and 15 of 22 patients (68%) had ≥1 CSF variant not detected in matched tissue, including clinically relevant alterations in EGFR , PMS2 , PIK3CA , and TP53 . CONCLUSION: The addition of intraoperatively acquired CSF liquid biopsy to tissue NGS in patients with GBM may improve detection of clinically relevant variants, potentially improving selection of patients for clinical trials.
Supplemental Figure 1. Patients and assays Supplemental Figure 2. Survival analysis at baseline and post-radiation Supplemental Figure 3. Correlative analysis of all ccfDNA deconvolution subsets with [ccfDNA]. Supplemental Figure 4. Analysis of % neutrophil tissue DNA and pre-operative steroids. Supplemental Figure 5. Correlative analysis of all ccfDNA deconvolution subsets with [citH3]. Supplemental Figure 6. Analysis of % neutrophil tissue DNA and [citH3]. Supplemental Figure 7. Analysis of [citH3], pre-operative steroid dose, and tumor volume. Supplemental Figure 8. Analysis of % neutrophil ccfDNA by steroid exposure. Supplemental Figure 9. Percent neutrophil ccfDNA and [citH3] at time of first post-radiation MRI. Supplemental Figure 10. Analysis of % neutrophil ccfDNA and total [ccfDNA] by steroid exposure. Supplemental Figure 11. Molecular sub-type analysis of Clusters 1 and 2 from plasma ccfDNA differential methylation results. Supplemental Figure 12. Unsupervised clustering of tissue DNA methylation data, differential methylation, and pathway analysis. Supplemental Figure 13. Analysis of Clusters 1 and 2 from tissue DNA differential methylation analysis. Supplemental Figure 14. Analysis of Clusters 1 and 2 from plasma ccfDNA differential methylation results.
List of all methylGSA results for (Gene Ontology,GO, gene sets) differential methylation comparing cluster 1 vs cluster 2 from unsupervised clustering of the plasma ccfDNA methylation results.